Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates

Human Gene Therapy

Volumn 17, Issue 1, 2006, Pages 31-45

  Naik, Arpana M ^a   Chalikonda, Sricharan ^b   McCart, J Andrea ^a   Xu, Hui ^a   Guo, Z Sheng ^b   Langham, Gregory ^a   Gardner, Donald ^c   Mocellin, Simone ^a   Lokshin, Anna E ^d   Moss, Bernard ^e   Alexander, H Richard ^a   Bartlett, David L ^a,b,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; VACCINIA VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; ARTICLE; CANCER GENETICS; CANCER PATIENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FECES LEVEL; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG URINE LEVEL; ERYTHEMA; FEMALE; FEVER; LETHARGY; LIMB PERFUSION; MALE; MUTANT VACCINIA VIRUS VECTOR; NECROSIS; NONHUMAN; PRIMATE; RHESUS MONKEY; SKIN MANIFESTATION; TISSUE LEVEL; TOXICITY TESTING; VACCINIA; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIREMIA; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; EXTREMITIES; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRADERMAL; INTERLEUKIN-6; LIVER; MACACA MULATTA; MALE; MUTATION; NEOPLASMS; PEPTIDES; PERFUSION; THYMIDINE KINASE; VACCINIA VIRUS;

ANIMALIA; MACACA MULATTA; PRIMATES; VACCINIA VIRUS;

EID: 30744464395     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.31     Document Type: Article

References (27)

1. ALEXANDER, H.R., FRAKER, D.L., and BARTLETT, D.L. (1996). Isolated limb perfusion for malignant melanoma. Semin. Surg. Oncol. 12, 416-428.
2. BARTLETT, D.L., LIBUTTI, S.K., FIGG, W.D., FRAKER, D.L., and ALEXANDER, H.R. (2001). Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129, 176-187.
3. CHANG, E., CHALIKONDA S., FRIEDL, J., XU, H., PHAN G.O., MARRINCOLA, F.M., ALEXANDER, H.R., and BARTLETT, D.L. (2005). Targeting vaccinia to solid tumor with local hyperthermia. Hum. Gene Ther. 16, 435-444.
4. CHRISTOFORIDIS, D., MARTINET, O., LEJEUNE, F.J., and MOSIMANN, F. (2002). Isolated liver perfusion for non-resectable liver tumours: A review. Eur. J. Surg. Oncol. 28, 875-890.
5. DE ROOS, W.K., FALLAUX, F.J., MARINELLI, A.W.K.S., LAZARIS-LARATZAS, A., VON GEUSAU, B.A., VAN DER EB, M.M., CRAMER, S.J., TERPSTRA, O.T., and HOEBEN, R.C. (1997). Isolated-organ perfusion for local gene delivery: Efficient adenovirus-mediated gene transfer into the liver. Gene Ther. 4, 55-62.
6. DE ROOS, W.K., DE WILT, J.H., DER KAADEN, M.E., MANUSAMA, E.R., DE VRIES, M.W., BOUT, A., TEN HAGEN, T.L., VALERIO, D., and EGGERMONT, A.M. (2000). Isolated limb perfusion for local gene delivery: Efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann. Surg. 232, 814-821.
7. EARL, P.L., and MOSS, B. (1998). Expression of proteins in mammalian cells using vaccinia viral vectors. In: Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., and Struhl, K., eds. Current Protocols in Molecular Biology. (Greene/Wiley Interscience, New York) pp. 16.15.1-16.19.9.
8. FREED, E.R., DUMA, R.J., and ESCOBAR, M.R. (1972). Vaccinia necrosum and its relationship to impaired immunologic responsiveness. Am. J. Med. 52, 411-420.
9. FRIEDL, J., TURNER, E., and ALEXANDER, H.R. (2003). Augmentation of endothelial cell monolayer permeability by hyperthermia but not tumor necrosis factor: Evidence for disruption of vascular integrity via VE-cadherin down-regulation. Int. J. Oncol. 23, 611-616.
10. GNANT, M., NOLL, L., IRVINE, K.R., PUHLMANN, M., TERRIL, R., ALEXANDER, H.R., and BARTLETT, D.L. (1999). Tumor specific gene delivery using recombinant vaccinia virus in a rabbit model of unresectable liver metastases: Pattern of gene expression, vector elimination and immune response. J. Natl. Cancer Inst. 91, 1744-1750.
11. GORELIK, E., LANDSITTEL, D.P., MARRANGONI, A.M., MODUGNO, F., VELIKOKHATNAYA, L., WINANS M.T., BIGBEE, W.L., HERBERMAN, R.B., and LOKSHIN A.E. (2005). Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14, 981-987.
12. HEID, C.A., STEVENS, J., LIVAK, K.J., and WILLIAMS, P.M. (1996). Real time quantitative PCR. Genome Res. 6, 986-994.
13. HERNAIZ DRIEVER, P., and RABKIN, S.D. (2001). Replication-competent viruses for cancer therapy. Monogr. Virol. 22, 1-187.
14. KIRN, D. (2002). Virotherapy for cancer: Current status, hurdles, and future directions. Cancer Gene Ther. 9, 959-960.
15. MCCART, J.A., PUHLMANN, M., LEE, J., HU, Y., LIBUTTI, S.K., ALEXANDER, H.R., and BARTLETT, D.L. (2000). Complex interactions between the replicating oncolytic effect and the enzyme/ prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 7, 1217-1223.
16. MCCART, J.A., WARD, J.M., LEE, J., HU, Y., ALEXANDER, H.R., LIBUTTI, S.K., MOSS, B., and BARTLETT, D.L. (2001). Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61, 8751-8757.
17. MOSS, B., CARROLL, M.W., WYATT, L.S., BENNINK, J.R., HIRSCH, V.M., GOLDSTEIN, S., ELKINS, W.R., FUERST, T.R., LIFSON, J.D., PIATAK, M., RESTIFO, N.P., OVERWIJK, W., CHAMBERLAIN, R., ROSENBERG, S.A., and SUTTER, G. (1996). Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397, 7-13.
18. NEEMAN, M., ABRAMOVITCH, R., SCHIFFENBAUER, Y.S., and TEMPEL, C. (1997). Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle. Int. J. Exp. Pathol. 78, 57-70.
19. NEFF, J.M., and LANE, J.M. (1970). Vaccinia necrosum following smallpox vaccination for chronic herpetic ulcers. JAMA 213, 123-125.
20. OLMSTED, R.A., BULLER, R.M., COLLINS, P.L., LONDON, W.T., BEELER, J.A., PRINCE, G.A., CHANOCK, R.M., and MURPHY, B.R. (1988). Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus. Vaccine 6, 519-524.
21. PEPLINSKI, G.R., TSUNG, K., CASEY, M.J., MEKO, J.B., FREDRICKSON, T.N., BULLER, R.M.L., and NORTON, J.A. (1996). In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1β. Cancer J. 2, 21-27.
22. PUHLMANN, M., GNANT, M., BROWN, C.K., ALEXANDER, H.R., and BARTLETT, D.L. (1999). Thymidine kinase deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor directed gene therapy. Hum. Gene Ther. 10, 649-657.
23. PUHLMANN, M., BROWN, C.K., GNANT, M., HUANG, J., LIBUTTI, S.K., ALEXANDER, H.R., and BARTLETT, D.L. (2000). Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther. 7, 66-73.
24. SCHNELL, M.A., ZHANG, Y., TAZELAAR, J. GAO, G., YU. Q.C., QIAN, R., CHEN, S., VARNAVSKI, A., LECLAIR, C., RAPER, S.E., and WILSON, J.M. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3, 708-722.
25. VARNAVSKI, A., ZHANG, Y., SCHNELL, M.A., TAZELAAR, J., LOUBOUTIN, J., YU, Q.C., BAGG, A., GAO, G., and WILSON, J.M. (2002). Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J. Virol. 76, 5711-5719.
26. WILLS, V.L., BOORER, C.J., FOSTER, H.M., HERSEY, P., and KESSON, A. (2000). Vaccinia necrosum: A forgotten disease. Aust. N.Z. J. Surg. 70, 149-150.
27. ZEH, H.J., and BARTLETT, D.L. (2002). Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. 9, 1001-1012.